

c) growing a tissue culture monolayer from said cohesive multicellular particulates;

d) inoculating cells from said monolayer into a plurality of segregated sites;

e) treating said plurality of sites with at least one agent;

f) examining said plurality of sites; and

g) assessing chemosensitivity of the cells in said plurality of sites.

38. The method according to claim 37, wherein said agent is at least one of the agents selected from a group consisting of a radiation therapy agent; a radiation therapy sensitizing agent; a radiation therapy desensitizing agent; an immunotherapeutic agent; a gene therapy agent; a combination chemotherapy agent; a hormone therapy agent; and a differentiating agent.

39. The method according to claim 38, wherein said agent is an immunotherapeutic agent.--

REMARKS

The undersigned thanks Examiner Gitomer for the courtesies extended in the telephone interview of May 4, 2001, the substance of which is being made of record herewith. New claims 37-39, which parallel the claims of U. S. Patent No. 5,728,541, are being submitted herewith with minor modifications but for the expansion of the tissue particle size to "about 0.25 mm³ - 1.5 mm³." This particle size range of the cohesive multicellular particulate represents a departure from the "about 1 mm³" limitation, which appears in the claims of issued U.S. Patent No. 5,728,541. Support for this size range appears, for instance, in Example 2.